

Moshe Talpaz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8789849/moshe-talpaz-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

405 papers	42,530 citations	96 h-index	200 g-index
422 ext. papers	46,587 ext. citations	6.9 avg, IF	6.71 L-index

#	Paper	IF	Citations
405	A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis. <i>Blood</i> , 2021 , 138, 139-139	2.2	4
404	Efficacy of HMA +/- Venetoclax or Intensive Chemotherapy in Blast-Phase Myeloproliferative Neoplasms. <i>Blood</i> , 2021 , 138, 2569-2569	2.2	1
403	Type 1 interferon to prevent leukemia relapse after allogeneic transplantation. <i>Blood Advances</i> , 2021 , 5, 5047-5056	7.8	1
402	Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial. <i>HemaSphere</i> , 2021 , 5, e553	0.3	1
401	Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial. <i>HemaSphere</i> , 2021 , 5, e562	0.3	8
400	A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management. <i>Blood Reviews</i> , 2021 , 45, 100691	11.1	5
399	Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. <i>Leukemia</i> , 2021 , 35, 1-17	10.7	47
398	The Interferon-Alpha Revival in CML. <i>Hematologic Malignancies</i> , 2021 , 197-226	0	
397	Downregulation of SOX2 by inhibition of Usp9X induces apoptosis in melanoma. <i>Oncotarget</i> , 2021 , 12, 160-172	3.3	2
396	Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. <i>JAMA Oncology</i> , 2021 , 7, 525-533	13.4	19
395	Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. <i>Blood</i> , 2021 , 138, 2042-2050	2.2	10
394	Remembering Emil J. Freireich: A Portrait of Courage and Innovation in Cancer Research March 16, 1927 to February 1, 2021. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2973-2976	2.2	1
393	Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. <i>Blood Advances</i> , 2020 , 4, 5825-5835	7.8	26
392	Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. <i>Clinical Cancer Research</i> , 2020 , 26, 1247-1257	12.9	29
391	Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. <i>American Journal of Hematology</i> , 2020 , 95, 594-603	7.1	45
390	Role of Aneuploidy in Transcriptional Regulation and Clinical Prognosis in Relapsed and/or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020 , 136, 45-46	2.2	0
389	Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1385-1415	7.3	42

388	ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. <i>Blood Advances</i> , 2020 , 4, 4282-4291	7.8	29
387	Fedratinib Induces Spleen Responses and Reduces Symptom Burden as First-line or Salvage Therapy in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) and Low Platelet Counts. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, S355	2	4
386	The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma. <i>Leukemia</i> , 2019 , 33, 2924-2933	10.7	23
385	SOHO State of the Art Updates and Next Questions: Myelofibrosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 191-199	2	0
384	Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. <i>Leukemia Research</i> , 2019 , 79, 38-44	2.7	20
383	MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis. <i>Blood</i> , 2019 , 134, 670-670	2.2	30
382	Tumor necrosis factor related apoptosis inducing ligand (TRAIL) regulates deubiquitinase USP5 in tumor cells. <i>Oncotarget</i> , 2019 , 10, 5745-5754	3.3	4
381	Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. <i>Lancet Haematology</i> , 2019 , 6, e630-e637	14.6	121
380	Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. <i>New England Journal of Medicine</i> , 2019 , 381, 2315-2326	59.2	114
379	Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth. <i>Oncogene</i> , 2019 , 38, 1576-1584	9.2	34
378	Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1036-1042	1.9	1
377	Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 652-659	13.4	133
376	Dasatinib dose management for the treatment of chronic myeloid leukemia. <i>Cancer</i> , 2018 , 124, 1660-1672	14	13
375	Usp9x Promotes Survival in Human Pancreatic Cancer and Its Inhibition Suppresses Pancreatic Ductal Adenocarcinoma In Vivo Tumor Growth. <i>Neoplasia</i> , 2018 , 20, 152-164	6.4	11
374	Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG. <i>Annals of Hematology</i> , 2018 , 97, 573-584	3	6
373	Phase 1 study of the PI3K inhibitor INCB040093 + JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. <i>Blood</i> , 2018 , 132, 293-306	2.2	32
372	Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, e201-e210	2	
371	Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. <i>Blood</i> , 2018 , 132, 393-404	2.2	221

370	Primary myelofibrosis evolving to an aplastic appearing marrow. <i>Clinical Case Reports (discontinued)</i> , 2018 , 6, 1393-1395	0.7	2
369	Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 101	22.4	15
368	Integrative Next Generation Sequencing of Myeloproliferative Neoplasms and Correlation of Genetic Variations to Disease Severity. <i>Blood</i> , 2018 , 132, 4324-4324	2.2	1
367	Oncologists' Use of Genomic Sequencing Data to Inform Clinical Management. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	3
366	Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 1500-1537	7.3	23
365	Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 1108-1135	7.3	132
364	The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia. <i>Leukemia Research</i> , 2018 , 70, 91-96	2.7	19
363	Induction of p53 suppresses chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1-14	1.9	7
362	Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. <i>Haematologica</i> , 2017 , 102, 327-335	6.6	66
361	Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 55	22.4	208
360	Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma. <i>Nature Communications</i> , 2017 , 8, 14449	17.4	33
359	Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 684-695.e6	2	25
358	Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. <i>Lancet Haematology</i> , 2017 , 4, e317-e324	14.6	148
357	Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis. <i>American Journal of Hematology</i> , 2017 , 92, 555-561	7.1	7
356	Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. <i>Haematologica</i> , 2017 , 102, 519-528	6.6	16
355	NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 1193-1207	7.3	77
354	Integrative clinical genomics of metastatic cancer. <i>Nature</i> , 2017 , 548, 297-303	50.4	440
353	Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. <i>Oncotarget</i> , 2017 , 8, 89848-89866	3.3	36

352	The Interferon Alpha Revival in CML. <i>Hematologic Malignancies</i> , 2016 , 207-230	0	
351	A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis. <i>Tomography</i> , 2016 , 2, 67-78	3.1	10
350	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2016 , 17, 612-21	21.7	164
349	Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. <i>Blood</i> , 2016 , 127, 2693-700	2.2	57
348	Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. <i>Blood</i> , 2016 , 127, 703-12	2.2	65
347	Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2259-67	1.9	13
346	Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. <i>Leukemia Research</i> , 2016 , 48, 84-91	2.7	88
345	The interferon-alpha revival in CML. <i>Annals of Hematology</i> , 2015 , 94 Suppl 2, S195-207	3	37
344	Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. <i>Cancer Cell</i> , 2015 , 27, 589-602	24.3	212
343	Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 913-25	27.4	257
342	Meir Wetzler, MD. <i>Cancer</i> , 2015 , 121, 2106-7	6.4	
341	Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 424-34	7.3	18
340	Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. <i>Journal of Translational Medicine</i> , 2015 , 13, 294	8.5	32
339	Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. <i>Haematologica</i> , 2015 , 100, 479-88	6.6	174
338	Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies. <i>Blood</i> , 2015 , 125, 3588-97	2.2	76
337	Ruxolitinib for the treatment of patients with polycythemia vera. <i>Expert Review of Hematology</i> , 2015 , 8, 391-401	2.8	6
336	CD24+ Ovarian Cancer Cells Are Enriched for Cancer-Initiating Cells and Dependent on JAK2 Signaling for Growth and Metastasis. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 1717-27	6.1	63
335	Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I). <i>Bioorganic and Medicinal Chemistry</i> , 2014 , 22, 1450-8	3.4	9

334	Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. <i>Haematologica</i> , 2014 , 99, 292-8	6.6	35
333	Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. <i>Blood</i> , 2014 , 124, 1038-46	2.2	171
332	Ponatinib in Philadelphia chromosome-positive leukemias. <i>New England Journal of Medicine</i> , 2014 , 370, 577	59.2	18
331	Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 3550-5	11.5	65
330	Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. <i>Leukemia Research</i> , 2014 , 38, 10-20	2.7	97
329	A New Prognostic Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers. <i>Blood</i> , 2014 , 124, 1842-1842	2.2	1
328	Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial. <i>Blood</i> , 2014 , 124, 3135-3135	3.3	35
327	Impact of Dose Intensity of Ponatinib on Selected Adverse Events: Multivariate Analyses from a Pooled Population of Clinical Trial Patients. <i>Blood</i> , 2014 , 124, 4546-4546	2.2	12
326	Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials. <i>Blood</i> , 2014 , 124, 4552-4552	2.2	8
325	Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7084-7084	2.2	11
324	Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway. <i>Oncotarget</i> , 2014 , 5, 5559-69	3.3	37
323	Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 71, 1599-607	3.5	21
322	Identification of targetable FGFR gene fusions in diverse cancers. <i>Cancer Discovery</i> , 2013 , 3, 636-47	24.4	511
321	Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. <i>Nature Genetics</i> , 2013 , 45, 180-5	36.3	514
320	Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1285-92	2.2	142
319	Activating ESR1 mutations in hormone-resistant metastatic breast cancer. <i>Nature Genetics</i> , 2013 , 45, 1446-51	36.3	742
318	The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. <i>British Journal of Haematology</i> , 2013 , 161, 508-16	4.5	69
317	Hematology clinic: chronic myelogenous leukemia. <i>Hematology</i> , 2013 , 18, 372-3	2.2	

316	Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. <i>Haematologica</i> , 2013 , 98, 217-21	6.6	55
315	Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. <i>Journal of Hematology and Oncology</i> , 2013 , 6, 81	22.4	81
314	Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study. <i>British Journal of Haematology</i> , 2013 , 162, 548-52	4.5	46
313	Re-emergence of interferon- γ in the treatment of chronic myeloid leukemia. <i>Leukemia</i> , 2013 , 27, 803-12	10.7	99
312	Overcoming resistance in chronic myeloid leukemia. <i>Clinical Investigation</i> , 2013 , 3, 817-821		
311	Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. <i>Haematologica</i> , 2013 , 98, 1865-71	6.6	128
310	Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs). <i>Blood</i> , 2013 , 122, 1496-1496	2.2	4
309	Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial. <i>Blood</i> , 2012 , 120, 163-163	2.2	7
308	Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML). <i>Blood</i> , 2013 , 122, 652-652	2.2	6
307	Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. <i>Blood</i> , 2012 , 119, 1981-7	2.2	249
306	A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. <i>New England Journal of Medicine</i> , 2012 , 366, 799-807	59.2	1377
305	Ponatinib in refractory Philadelphia chromosome-positive leukemias. <i>New England Journal of Medicine</i> , 2012 , 367, 2075-88	59.2	556
304	A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial. <i>Blood</i> , 2012 , 120, 163-163	2.2	23
303	A Phase II Randomized Dose-Ranging Study of the JAK2-Selective Inhibitor SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF.. <i>Blood</i> , 2012 , 120, 2837-2837	2.2	6
302	Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial. <i>Blood</i> , 2012 , 120, 3747-3747	2.2	6
301	Managing resistance in chronic myeloid leukemia. <i>Blood Reviews</i> , 2011 , 25, 279-90	11.1	50
300	Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. <i>Blood</i> , 2011 , 117, 3151-62	2.2	93
299	Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. <i>Blood</i> , 2011 , 118, 3051-61	2.2	102

298	NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9 Suppl 2, S1-25	7.3	31
297	Protein cross-linking as a novel mechanism of action of a ubiquitin-activating enzyme inhibitor with anti-tumor activity. <i>Biochemical Pharmacology</i> , 2011 , 82, 341-9	6	27
296	Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma. <i>Bioorganic and Medicinal Chemistry</i> , 2011 , 19, 7194-204	3.4	6
295	A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination. <i>Cellular Signalling</i> , 2011 , 23, 2076-85	4.9	34
294	Personalized oncology through integrative high-throughput sequencing: a pilot study. <i>Science Translational Medicine</i> , 2011 , 3, 111ra121	17.5	452
293	Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. <i>Journal of Clinical Oncology</i> , 2011 , 29, 789-96	2.2	328
292	NF1 inactivation in adult acute myelogenous leukemia. <i>Clinical Cancer Research</i> , 2010 , 16, 4135-47	12.9	54
291	Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. <i>Cancer Research</i> , 2010 , 70, 9265-76	10.1	263
290	Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. <i>Blood</i> , 2010 , 116, 4958-67	2.2	64
289	Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia. <i>Biochemical Pharmacology</i> , 2010 , 79, 688-97	6	26
288	PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal. <i>PLoS ONE</i> , 2010 , 5, e11770	3.7	28
287	Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. <i>Clinical Cancer Research</i> , 2009 , 15, 3850-5	12.9	22
286	Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5015-22	2.2	67
285	Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. <i>Hematology American Society of Hematology Education Program</i> , 2009 , 461-76	3.1	132
284	NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7, 984-1023	7.3	103
283	Inhibition of Cytokine Signaling through Activation of Jak2 Ubiquitination by WP1130.. <i>Blood</i> , 2009 , 114, 2907-2907	2.2	
282	De-Ubiquitinase Inhibition by WP1130 Induces Formation of Aggresomes, Engages Autophagy and Activates Apoptosis in B-Cell Malignancies.. <i>Blood</i> , 2009 , 114, 3769-3769	2.2	
281	WP1130 Inhibits Signaling through BCR-ABL Ubiquitination and Cytoplasmic to Aggresome Trafficking to Induce Apoptosis of CML Cells.. <i>Blood</i> , 2009 , 114, 3303-3303	2.2	

280	Cell-cycle deregulation in progressive CML. <i>Nature Reviews Cancer</i> , 2008 , 8, 563-563	31.3	
279	Getting to the stem of chronic myeloid leukaemia. <i>Nature Reviews Cancer</i> , 2008 , 8, 341-50	31.3	151
278	Molecular analysis of chromosome 22 breakpoints in adult Philadelphia-positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2008 , 67, 55-59	4.5	2
277	Efficacy of various doses and schedules of second-generation tyrosine kinase inhibitors. <i>Clinical Lymphoma and Myeloma</i> , 2008 , 8 Suppl 3, S95-S106		6
276	Dasatinib Resistance in Patients with Chronic Myelogenous Leukemia: Identification of a Novel bcr-abl Kinase Domain Mutation. <i>Clinical Leukemia</i> , 2008 , 2, 267-271		3
275	Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 111, 1584-93	2.2	103
274	Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 926-39	9.7	133
273	Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. <i>Blood</i> , 2008 , 111, 1039-43	2.2	175
272	Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. <i>Blood</i> , 2008 , 111, 3821-9	2.2	90
271	Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph++ Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation. <i>Blood</i> , 2008 , 112, 3232-3232	2.2	23
270	Degrasyn (a novel tyrophostin) Impacts BCR-ABL Protein Level and Is Cytotoxic to Chronic Myeloid Leukemia Early Progenitors. <i>Blood</i> , 2008 , 112, 3212-3212	2.2	
269	Strategies for overcoming imatinib resistance in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2007 , 48, 2310-22	1.9	29
268	Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. <i>Blood</i> , 2007 , 109, 4143-50	2.2	321
267	Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. <i>Cancer</i> , 2007 , 109, 1556-60	6.4	75
266	Degrasyn activates proteasomal-dependent degradation of c-Myc. <i>Cancer Research</i> , 2007 , 67, 3912-8	10.1	35
265	Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. <i>Blood</i> , 2007 , 109, 3470-8	2.2	77
264	Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. <i>Blood</i> , 2007 , 109, 497-9	2.2	137
263	The role of interferon-alpha in the treatment of chronic myeloid leukemia. <i>Cytokine and Growth Factor Reviews</i> , 2007 , 18, 459-71	17.9	60

262	Mutational Analysis of Chronic Myeloid Leukemia (CML) Clones Reveals Heightened BCR-ABL1 Genetic Instability and Wild-Type BCR-ABL1 Exhaustion in Patients Failing Sequential Imatinib and Dasatinib Therapy.. <i>Blood</i> , 2007 , 110, 1938-1938	2.2	3
261	Dasatinib Resistance in CML Patients. Identification of Novel BCR-ABL Kinase Domain Mutation.. <i>Blood</i> , 2007 , 110, 1957-1957	2.2	1
260	Comprehensive Biomarker and Genomic Analysis Identifies p53 Status as the Major Determinant of Response to MDM2 Inhibitors in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2007 , 110, 224-224	2.2	
259	A Novel Small-Molecule Approach To Inhibit Jak2 Tyrosine Kinase Signaling.. <i>Blood</i> , 2007 , 110, 1556-1556.	2.2	
258	Degrasyn-Induced Trafficking of BCR-ABL as a Novel Mechanism of Kinase Inactivation.. <i>Blood</i> , 2007 , 110, 1003-1003	2.2	
257	Pilot study of Ionafernib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. <i>Cancer</i> , 2006 , 106, 346-52	6.4	60
256	Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. <i>Cancer</i> , 2006 , 106, 1306-15	6.4	78
255	Pregnancy among patients with chronic myeloid leukemia treated with imatinib. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1204-8	2.2	183
254	Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. <i>New England Journal of Medicine</i> , 2006 , 354, 2531-41	59.2	1414
253	New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. <i>Annals of Internal Medicine</i> , 2006 , 145, 913-23	8	187
252	Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1651-64	1.9	4
251	Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. <i>Blood</i> , 2006 , 107, 2501-6	2.2	65
250	The TNF receptor, RELT, binds SPAK and uses it to mediate p38 and JNK activation. <i>Biochemical and Biophysical Research Communications</i> , 2006 , 343, 125-34	3.4	32
249	TRAIL-induced cleavage and inactivation of SPAK sensitizes cells to apoptosis. <i>Biochemical and Biophysical Research Communications</i> , 2006 , 349, 1016-24	3.4	9
248	Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. <i>Blood</i> , 2006 , 108, 1835-40	2.2	181
247	Inhibition of JAK2/STAT Signaling by Degrasyn through a Novel Mechanism.. <i>Blood</i> , 2006 , 108, 3423-3423.	2.2	
246	Bortezomib Synergizes with a Novel Jak2 Inhibitor, WP-1130, To Inhibit Cell Growth and Induce Apoptosis in Classic and Blastoid-Variant Mantle Cell Lymphoma.. <i>Blood</i> , 2006 , 108, 2512-2512	2.2	
245	Activity of ABL Kinase Inhibitors in Two Distinct Models of Imatinib Resistance.. <i>Blood</i> , 2006 , 108, 4819-4819	2.2	

244	A Novel BCR-ABL Mutation Predicts Resistance to Tyrosine Kinase Inhibitor (TKI) Therapy by a Unique Mechanism in Patients (pts) with Philadelphia-Positive (Ph+) Leukemia.. <i>Blood</i> , 2006 , 108, 4773-4773		
243	Lyn Kinase Alters Gab2 Phosphorylation and c-Cbl Protein Levels To Regulate Imatinib Sensitivity and Survival of Chronic Myelogenous Leukemia Cells.. <i>Blood</i> , 2006 , 108, 2132-2132	2.2	
242	Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. <i>Mayo Clinic Proceedings</i> , 2005 , 80, 390-402	6.4	46
241	The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. <i>Leukemia and Lymphoma</i> , 2005 , 46, 993-7	1.9	23
240	Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. <i>Blood</i> , 2005 , 105, 2281-6	2.2	92
239	Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience. <i>Cancer</i> , 2005 , 103, 2099-108	6.4	57
238	Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986. <i>Cancer</i> , 2005 , 103, 2551-7	6.4	19
237	Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. <i>Cancer</i> , 2005 , 104, 777-80	6.4	22
236	Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. <i>Clinical Cancer Research</i> , 2005 , 11, 6247-55	12.9	30
235	Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3948-56	2.2	259
234	Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. <i>Clinical Cancer Research</i> , 2005 , 11, 3425-32	12.9	237
233	Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. <i>Clinical Cancer Research</i> , 2005 , 11, 6924-32	12.9	277
232	Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. <i>Clinical Cancer Research</i> , 2004 , 10, 68-75	12.9	49
231	Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. <i>Cancer Research</i> , 2004 , 64, 672-7	10.1	199
230	Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. <i>British Journal of Haematology</i> , 2004 , 125, 187-95	4.5	70
229	The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. <i>Cancer</i> , 2004 , 100, 116-21	6.4	97
228	Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. <i>Cancer</i> , 2004 , 100, 2592-7	6.4	53
227	Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2004 , 100, 2396-402	6.4	32

226	Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. <i>Cancer</i> , 2004 , 101, 332-6	6.4	56
225	Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. <i>Journal of Clinical Oncology</i> , 2004 , 22, 935-42	2.2	391
224	Investigational strategies in chronic myelogenous leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2004 , 18, 619-39, ix	3.1	6
223	The Role of Imatinib in the Treatment of Chronic Myelogenous Leukemia. <i>American Journal of Cancer</i> , 2004 , 3, 337-348		
222	High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. <i>Blood</i> , 2004 , 103, 2873-8	2.2	344
221	Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. <i>Blood</i> , 2004 , 103, 3175-84	2.2	277
220	Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. <i>Blood</i> , 2004 , 103, 4396-407	2.2	458
219	Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. <i>Blood</i> , 2004 , 104, 1979-88	2.2	144
218	Hematologic and Cytogenetic Responses in Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study.. <i>Blood</i> , 2004 , 104, 1-1	2.2	25
217	Hematologic and Cytogenetic Responses in Imatinib-Resistant Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study.. <i>Blood</i> , 2004 , 104, 20-20	2.2	17
216	Effects of Adaphostin, a Novel Tyrphostin Inhibitor, in Diverse Models of Imatinib Mesylate Resistance.. <i>Blood</i> , 2004 , 104, 2097-2097	2.2	1
215	Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials.. <i>Blood</i> , 2004 , 104, 23-23	2.2	39
214	TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. <i>Journal of Biological Chemistry</i> , 2003 , 278, 32317-23	5.4	121
213	Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. <i>Blood</i> , 2003 , 101, 473-5	2.2	273
212	Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. <i>Blood</i> , 2003 , 101, 1692-7	2.2	193
211	Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. <i>Blood</i> , 2003 , 101, 3794-800	2.2	183
210	Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. <i>Blood</i> , 2003 , 102, 4527-34	2.2	117
209	Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. <i>Blood</i> , 2003 , 102, 987-95	2.2	268

208	Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. <i>Blood</i> , 2003 , 102, 83-6	2.2	164
207	Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. <i>Blood</i> , 2003 , 101, 97-100	2.2	128
206	Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. <i>Blood</i> , 2003 , 102, 630-7	2.2	47
205	Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. <i>Cancer</i> , 2003 , 97, 1033-41	6.4	190
204	Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. <i>Cancer</i> , 2003 , 97, 2225-8	6.4	21
203	Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. <i>Cancer</i> , 2003 , 97, 2760-6	6.4	96
202	Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. <i>Cancer</i> , 2003 , 97, 3010-6	6.4	9
201	Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. <i>Cancer</i> , 2003 , 98, 81-5	6.4	41
200	Chronic myelogenous leukemia: a review and update of therapeutic strategies. <i>Cancer</i> , 2003 , 98, 437-57	6.4	61
199	Results of decitabine (5-aza-2'-deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. <i>Cancer</i> , 2003 , 98, 522-8	6.4	200
198	Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. <i>Cancer</i> , 2003 , 98, 888-93	6.4	62
197	Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. <i>Cancer</i> , 2003 , 98, 1105-13	6.4	74
196	Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. <i>Cancer</i> , 2003 , 98, 1430-7	6.4	16
195	Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. <i>Cancer</i> , 2003 , 98, 1905-11	6.4	114
194	Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses. <i>Cancer</i> , 2003 , 98, 2410-9	6.4	17
193	Imatinib mesylate causes hypopigmentation in the skin. <i>Cancer</i> , 2003 , 98, 2483-7	6.4	111
192	Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. <i>Cancer</i> , 2003 , 98, 2636-42	6.4	77
191	Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. <i>Leukemia Research</i> , 2003 , 27, 1091-6	2.7	20

190	Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. <i>Annals of Internal Medicine</i> , 2003 , 138, 819-30	8	223
189	BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. <i>Blood</i> , 2003 , 101, 690-8	2.2	574
188	Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. <i>Clinical Cancer Research</i> , 2003 , 9, 160-6	12.9	67
187	Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. <i>Clinical Cancer Research</i> , 2003 , 9, 976-80	12.9	64
186	Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia. <i>Cancer</i> , 2002 , 94, 1517-21	6.4	15
185	Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. <i>Cancer</i> , 2002 , 94, 2024-32	6.4	58
184	Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. <i>Cancer</i> , 2002 , 94, 2416-25	6.4	52
183	Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. <i>Cancer</i> , 2002 , 94, 2996-9	6.4	19
182	Reduced focal adhesion kinase and paxillin phosphorylation in BCR-ABL-transfected cells. <i>Cancer</i> , 2002 , 95, 440-50	6.4	22
181	Severe periorbital edema secondary to STI571 (Gleevec). <i>Cancer</i> , 2002 , 95, 881-7	6.4	112
180	Cellular signalling pathways: new targets in leukaemia therapy. <i>British Journal of Haematology</i> , 2002 , 116, 57-77	4.5	21
179	Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival. <i>British Journal of Haematology</i> , 2002 , 119, 38-45	4.5	33
178	STI-571 in chronic myelogenous leukaemia. <i>British Journal of Haematology</i> , 2002 , 119, 15-24	4.5	21
177	Current therapy of chronic myelogenous leukemia. <i>Internal Medicine</i> , 2002 , 41, 254-64	1.1	14
176	Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. <i>Blood</i> , 2002 , 99, 3547-53	2.2	251
175	Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. <i>Blood</i> , 2002 , 99, 1928-37	2.2	850
174	Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. <i>Blood</i> , 2002 , 99, 3530-9	2.2	986
173	Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. <i>New England Journal of Medicine</i> , 2002 , 346, 645-52	59.2	1693

172	Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. <i>Blood</i> , 2002 , 100, 1590-1595	2.2	135
171	Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. <i>Clinical Cancer Research</i> , 2002 , 8, 2167-76	12.9	72
170	Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. <i>Clinical Cancer Research</i> , 2002 , 8, 2177-87	12.9	84
169	Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon alpha: involvement of tumor necrosis factor as ligand for the CD95 receptor. <i>Blood</i> , 2001 , 97, 2791-7	2.2	14
168	Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes. <i>Blood</i> , 2001 , 98, 1773-81	2.2	53
167	Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. <i>Blood</i> , 2001 , 97, 2846-53	2.2	46
166	Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. <i>Blood</i> , 2001 , 98, 1708-13	2.2	62
165	Chronic myelogenous leukemia in chronic phase. <i>Current Treatment Options in Oncology</i> , 2001 , 2, 245-52	5.4	5
164	Translocation t(17;18)(q10;q10). <i>Cancer</i> , 2001 , 91, 1704-1708	6.4	7
163	Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. <i>Cancer</i> , 2001 , 91, 1964-72	6.4	37
162	Homoharringtonine: history, current research, and future direction. <i>Cancer</i> , 2001 , 92, 1591-605	6.4	155
161	Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. <i>Cancer</i> , 2001 , 92, 2501-7	6.4	19
160	Imatinib mesylate: Clinical results in Philadelphia chromosome-positive leukemias. <i>Seminars in Oncology</i> , 2001 , 28, 9-18	5.5	30
159	Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. <i>New England Journal of Medicine</i> , 2001 , 344, 1031-7	59.2	4179
158	Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. <i>New England Journal of Medicine</i> , 2001 , 344, 1038-42	59.2	2309
157	Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2001 , 7, 568-75	4.7	49
156	Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition. <i>Seminars in Hematology</i> , 2001 , 38, 22-7	4	22
155	Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase. <i>Leukemia and Lymphoma</i> , 2001 , 41, 309-19	1.9	11

154	BCR rearrangement-negative chronic myelogenous leukemia revisited. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2915-26	2.2	79
153	Pilot study of low-dose interleukin-11 in patients with bone marrow failure. <i>Journal of Clinical Oncology</i> , 2001 , 19, 4165-72	2.2	55
152	Imatinib mesylate: Clinical results in philadelphia chromosome-positive leukemias. <i>Seminars in Oncology</i> , 2001 , 28, 9-18	5.5	109
151	Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients. <i>FASEB Journal</i> , 2000 , 14, 1529-38	0.9	25
150	Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies. <i>Hematology American Society of Hematology Education Program</i> , 2000 , 90-109	3.1	15
149	Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy. <i>Cancer</i> , 2000 , 88, 570-6	6.4	10
148	Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon-alpha: a synergistic correlation?. <i>Cancer</i> , 2000 , 89, 1482-9	6.4	14
147	Therapeutic choices in younger patients with chronic myelogenous leukemia. <i>Cancer</i> , 2000 , 89, 1647-58	6.4	17
146	Cytoplasmic and nuclear localization of the 130 and 160 kDa Bcr proteins. <i>Leukemia</i> , 2000 , 14, 1892-7	10.7	6
145	Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients. <i>FASEB Journal</i> , 2000 , 14, 1529-1538	0.9	40
144	Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3513-21	2.2	73
143	Acute pancreatitis associated with interferon alpha therapy for chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2000 , 39, 647-50	1.9	9
142	Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies. <i>Hematology American Society of Hematology Education Program</i> , 2000 , 2000, 90-109	3.1	1
141	Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies. <i>Hematology American Society of Hematology Education Program</i> , 2000 , 2000, 90-109	3.1	5
140	Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. <i>Journal of Clinical Oncology</i> , 1999 , 17, 284-92	2.2	126
139	Phenylarsine Oxide Blocks Interleukin-1Induced Activation of the Nuclear Transcription Factor NF-B, Inhibits Proliferation, and Induces Apoptosis of Acute Myelogenous Leukemia Cells. <i>Blood</i> , 1999 , 94, 2844-2853	2.2	69
138	Sequential Homoharringtonine and Interferon-? in the Treatment of Early Chronic Phase Chronic Myelogenous Leukemia. <i>Blood</i> , 1999 , 93, 4149-4153	2.2	93
137	Methylation of the ABL1 Promoter in Chronic Myelogenous Leukemia: Lack of Prognostic Significance. <i>Blood</i> , 1999 , 93, 2075-2080	2.2	65

136	Should Polymerase Chain Reaction Analysis to Detect Minimal Residual Disease in Patients With Chronic Myelogenous Leukemia Be Used in Clinical Decision Making?. <i>Blood</i> , 1999 , 93, 2755-2759	2.2	75
135	Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 1999 , 35, 483-9	1.9	12
134	A pilot study of recombinant human interleukin-4 therapy of myelofibrosis. <i>Journal of Interferon and Cytokine Research</i> , 1999 , 19, 1253-5	3.5	2
133	Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance. <i>British Journal of Haematology</i> , 1999 , 107, 581-6	4.5	47
132	Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia. <i>Cancer</i> , 1999 , 85, 2583-2588	6.4	44
131	Multidrug resistance protein expression in chronic myeloid leukemia 1999 , 86, 805-813		26
130	Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. <i>Cancer</i> , 1999 , 86, 2632-41	6.4	143
129	Chronic myelogenous leukemia: biology and therapy. <i>Annals of Internal Medicine</i> , 1999 , 131, 207-19	8	322
128	The biology of chronic myeloid leukemia. <i>New England Journal of Medicine</i> , 1999 , 341, 164-72	59.2	969
127	Should Polymerase Chain Reaction Analysis to Detect Minimal Residual Disease in Patients With Chronic Myelogenous Leukemia Be Used in Clinical Decision Making?. <i>Blood</i> , 1999 , 93, 2755-2759	2.2	12
126	Sequential Homoharringtonine and Interferon-? in the Treatment of Early Chronic Phase Chronic Myelogenous Leukemia. <i>Blood</i> , 1999 , 93, 4149-4153	2.2	
125	DNA in situ hybridization of individual colonies to determine lineage derivation in leukemia. <i>Leukemia</i> , 1998 , 12, 242-6	10.7	2
124	GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. <i>Leukemia</i> , 1998 , 12, 860-4	10.7	41
123	Interleukin-1 increases expression of the LYT-10 (NFkappaB2) proto-oncogene/transcription factor in renal cell carcinoma lines. <i>Translational Research</i> , 1998 , 131, 261-8		3
122	Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemia. <i>Leukemia Research</i> , 1998 , 22, 341-53	2.7	29
121	Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. <i>Hematology/Oncology Clinics of North America</i> , 1998 , 12, 31-80	3.1	49
120	Local cutaneous necrotizing lesions associated with interferon injections. <i>Journal of Interferon and Cytokine Research</i> , 1998 , 18, 823-7	3.5	13
119	Serum cytokine levels in infectious mononucleosis at diagnosis and convalescence. <i>Leukemia and Lymphoma</i> , 1998 , 30, 583-9	1.9	20

118	Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation. <i>Leukemia and Lymphoma</i> , 1998 , 30, 279-92	1.9	12
117	High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. <i>Leukemia and Lymphoma</i> , 1998 , 30, 563-71	1.9	39
116	Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. <i>Journal of Clinical Oncology</i> , 1998 , 16, 1526-31	2.2	54
115	Caspase 2 and Caspase 3 Protein Levels as Predictors of Survival in Acute Myelogenous Leukemia. <i>Blood</i> , 1998 , 92, 3090-3097	2.2	112
114	Clinical Significance of Cytogenetic Abnormalities in Adult Acute Lymphoblastic Leukemia. <i>Blood</i> , 1998 , 91, 3995-4019	2.2	267
113	Loss of Imprinting in Disease Progression in Chronic Myelogenous Leukemia. <i>Blood</i> , 1998 , 91, 3144-3147	2.2	71
112	Clinical Significance of Cytogenetic Abnormalities in Adult Acute Lymphoblastic Leukemia. <i>Blood</i> , 1998 , 91, 3995-4019	2.2	5
111	Apoptosis in chronic myelogenous leukemia: studies of stage-specific differences. <i>Leukemia and Lymphoma</i> , 1997 , 25, 121-33	1.9	13
110	Role of interleukin-1 beta converting enzyme (ICE) in acute myelogenous leukemia cell proliferation and programmed cell death. <i>Leukemia and Lymphoma</i> , 1997 , 24, 379-91	1.9	6
109	Second cancer risk in hairy cell leukemia: analysis of 350 patients. <i>Journal of Clinical Oncology</i> , 1997 , 15, 1803-10	2.2	93
108	Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. <i>Annals of Internal Medicine</i> , 1997 , 127, 186-94	8	88
107	Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up. <i>Leukemia</i> , 1997 , 11, 42-7	10.7	64
106	Natural history and staging of chronic myelogenous leukaemia. <i>Best Practice and Research: Clinical Haematology</i> , 1997 , 10, 277-90		17
105	The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemia. <i>Best Practice and Research: Clinical Haematology</i> , 1997 , 10, 291-305		9
104	Suppressed formation of bone marrow adherent layers derived from acute myeloid leukemia patients after in vitro exposure to interleukin-4. <i>Leukemia Research</i> , 1997 , 21, 519-27	2.7	2
103	Thiotepa for the treatment of thrombocytopenia in patients with Philadelphia chromosome positive chronic myelogenous leukemia. <i>Cancer</i> , 1997 , 80, 396-400	6.4	1
102	Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha. <i>Leukemia and Lymphoma</i> , 1996 , 23, 247-52	1.9	22
101	Chronic myelogenous leukemia: a review. <i>American Journal of Medicine</i> , 1996 , 100, 555-70	2.4	123

100	Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. <i>American Journal of Medicine</i> , 1996 , 100, 452-5	2.4	36
99	Chromatin nucleoprotein complexes containing tightly bound c-abl, p53 and bcl-2 gene sequences: correlation with progression of chronic myelogenous leukemia. <i>Gene</i> , 1996 , 169, 173-8	3.8	6
98	Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients. <i>American Journal of Clinical Pathology</i> , 1996 , 106, 442-8	1.9	18
97	Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: Implications for the treatment of patients with metastatic melanoma. <i>Cancer</i> , 1996 , 77, 893-899	6.4	22
96	Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways. <i>International Journal of Cancer</i> , 1996 , 66, 515-9	7.5	59
95	Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181). <i>Journal of Cellular Physiology</i> , 1996 , 166, 618-30	7	28
94	Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia. <i>Leukemia Research</i> , 1995 , 19, 23-34	2.7	43
93	Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. <i>Journal of Clinical Oncology</i> , 1995 , 13, 575-82	2.2	151
92	Cell cycle-related shifts in subcellular localization of BCR: association with mitotic chromosomes and with heterochromatin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 3488-92	11.5	17
91	Interferon-alpha directly inhibits DNA polymerase activity in isolated chromatin nucleoprotein complexes: correlation with IFN-alpha treatment outcome in patients with chronic myelogenous leukemia. <i>Gene</i> , 1995 , 159, 105-11	3.8	7
90	Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. <i>American Journal of Medicine</i> , 1995 , 98, 551-8	2.4	60
89	Interferon-alpha therapy for chronic myelogenous leukemia. <i>American Journal of Medicine</i> , 1995 , 99, 402-11	2.4	45
88	Leukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation. <i>Journal of Interferon and Cytokine Research</i> , 1995 , 15, 905-13	3.5	40
87	Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results. <i>Cancer</i> , 1995 , 75, 464-70	6.4	47
86	Abnormalities in the PRAD1 (CYCLIN D1/BCL-1) oncogene are frequent in cervical and vulvar squamous cell carcinoma cell lines. <i>Cancer</i> , 1995 , 75, 584-90	6.4	44
85	Transformation of chronic lymphocytic leukemia to lymphoma of true histiocytic type. <i>Cancer</i> , 1995 , 76, 609-17	6.4	29
84	The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations. <i>Cancer</i> , 1995 , 76, 992-7	6.4	23
83	Low-dose interferon-alpha in chronic myeloid leukemia. <i>Annals of Internal Medicine</i> , 1995 , 122, 728-9	8	3

82 The Use of Growth Factor Receptor Inhibitors in Human Neoplasms **1994**, 178-195

81	Interleukin 4 alters human bone marrow stroma and modulates its interaction with hematopoietic progenitors. <i>Stem Cells</i> , 1994 , 12, 638-49	5.8	5
80	What is the contribution of molecular studies to the diagnosis of BCR-ABL-positive disease in adult acute leukemia?. <i>American Journal of Medicine</i> , 1994 , 96, 133-8	2.4	12
79	Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. <i>American Journal of Medicine</i> , 1993 , 94, 69-74	2.4	91
78	Use of two retroviral markers to test relative contribution of marrow and peripheral blood autologous cells to recovery after preparative therapy. The University of Texas M.D. Anderson Cancer Center. Division of Medicine. <i>Human Gene Therapy</i> , 1993 , 4, 71-85	4.8	13
77	Genetic therapy of human neoplastic disease. <i>Stem Cells and Development</i> , 1993 , 2, 373-5		
76	CML: mechanisms of disease initiation and progression. <i>Leukemia and Lymphoma</i> , 1993 , 11 Suppl 1, 47-50.	2.9	23
75	Long-term follow-up results of alpha interferon therapy in chronic myelogenous leukemia at M. D. Anderson Cancer Center. <i>Leukemia and Lymphoma</i> , 1993 , 11 Suppl 1, 169-74	1.9	8
74	Role of interleukin-1 inhibitory molecules in therapy of acute and chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 1993 , 10, 407-18	1.9	14
73	Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines. <i>Journal of Experimental Medicine</i> , 1993 , 177, 763-74	16.6	71
72	All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome. <i>Journal of Clinical Oncology</i> , 1993 , 11, 1489-95	2.2	47
71	Granulocyte-macrophage colony-stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinoma. <i>Journal of Internal Medicine</i> , 1993 , 234, 417-20	10.8	48
70	Analysis of the effects of tumor necrosis factor inhibitors on human hematopoiesis. <i>Stem Cells</i> , 1993 , 11, 112-9	5.8	17
69	Therapy of chronic myelogenous leukemia. <i>Stem Cells</i> , 1993 , 11 Suppl 3, 8-9	5.8	5
68	Molecular approaches to the diagnosis and treatment of cancer. <i>Stem Cells</i> , 1993 , 11 Suppl 3, 129-30	5.8	1
67	Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. <i>Journal of Clinical Investigation</i> , 1993 , 92, 1925-39	15.9	140
66	New Directions in the Biology and Therapy of Chronic Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 1992 , 6, 89-95	1.9	5
65	Use of cell-free retroviral vector preparations for transduction of cells from the marrow of chronic phase and blast crisis chronic myelogenous leukemia patients and from normal individuals. <i>Human Gene Therapy</i> , 1992 , 3, 137-45	4.8	15

64	The modulatory hematopoietic activities of leukemia inhibitory factor. <i>Leukemia and Lymphoma</i> , 1992 , 8, 1-7	1.9	5
63	Identification of a complex formed between nuclear proteins and the transcriptional enhancer of interferon-inducible genes that is present in the peripheral blood myeloid cells of CML but not normal individuals. <i>Journal of Interferon Research</i> , 1992 , 12, 323-7		
62	Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia. <i>American Journal of Medicine</i> , 1992 , 93, 41-8	2.4	25
61	Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia. <i>Cancer</i> , 1992 , 69, 410-2	6.4	20
60	Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. <i>Annals of Internal Medicine</i> , 1991 , 114, 532-8	8	295
59	Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low- over high-dose administration in selected patients. <i>British Journal of Haematology</i> , 1991 , 78, 352-8	4.5	29
58	Activation of class I HLA expression by TNF-alpha and gamma-interferon is mediated through protein kinase C-dependent pathway in CML cell lines. <i>British Journal of Haematology</i> , 1991 , 78, 359-67	4.5	4
57	Hairy cell leukaemia: review of treatment. <i>British Journal of Haematology</i> , 1991 , 79 Suppl 1, 17-20	4.5	18
56	The molecular pathology of chronic myelogenous leukaemia. <i>British Journal of Haematology</i> , 1991 , 79 Suppl 1, 34-7	4.5	15
55	Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1991 , 77, 291-5	4.5	69
54	Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies. <i>Cancer</i> , 1991 , 67, 990-6	6.4	92
53	Extramedullary blast crisis in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic remission. <i>Cancer</i> , 1991 , 67, 1946-9	6.4	9
52	Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia. <i>Cancer</i> , 1991 , 67, 2959-65	6.4	27
51	Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. <i>Cancer</i> , 1991 , 68, 1201-7	6.4	39
50	Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. <i>Cancer</i> , 1991 , 68, 1536-7	6.4	102
49	A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia. <i>Cancer</i> , 1991 , 68, 2125-30	6.4	21
48	Granulocyte-macrophage colony-stimulating factor and interleukin-3 in combination: a potent and consistent myelodysplastic syndrome bone marrow stimulant in vitro. <i>Annals of Hematology</i> , 1991 , 63, 297-301	3	9
47	Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 1991 , 33, 238-46	7.4	14

46	A phase I trial of recombinant alpha-2a interferon (Roferon-A) with weekly cisplatinum. <i>Investigational New Drugs</i> , 1991 , 9, 37-9	4.3	10
45	Molecular analysis of retroviral transduction in chronic myelogenous leukemia. <i>Human Gene Therapy</i> , 1991 , 2, 317-21	4.8	9
44	Treatment of cyclic neutropenia with very low doses of GM-CSF. <i>American Journal of Medicine</i> , 1991 , 91, 317-8	2.4	13
43	Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. <i>Journal of Clinical Oncology</i> , 1991 , 9, 1241-50	2.2	118
42	Alpha interferon dose-dependent suppression of secondary clones in a patient with Philadelphia-positive chronic myelogenous leukemia. <i>Acta Haematologica</i> , 1990 , 83, 149-51	2.7	4
41	Philadelphia Chromosome-Negative Chronic Myelogenous Leukemia and Chronic Myelomonocytic Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 1990 , 4, 389-404	3.1	38
40	Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. <i>American Journal of Medicine</i> , 1990 , 88, 1-8	2.4	243
39	A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. <i>American Journal of Medicine</i> , 1990 , 89, 663-72	2.4	103
38	Phase I study of a combination of recombinant tumor necrosis factor-alpha and recombinant interferon-gamma in cancer patients. <i>Journal of Interferon Research</i> , 1989 , 9, 435-44		16
37	Therapy of chronic myelogenous leukemia with interferon. <i>Cancer Investigation</i> , 1989 , 7, 83-91	2.1	6
36	Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis. <i>American Journal of Medicine</i> , 1989 , 86, 554-8	2.4	37
35	Characteristics of accelerated disease in chronic myelogenous leukemia. <i>Cancer</i> , 1988 , 61, 1441-6	6.4	208
34	Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. <i>Cancer</i> , 1988 , 62, 672-6	6.4	42
33	The molecular genetics of Philadelphia chromosome-positive leukemias. <i>New England Journal of Medicine</i> , 1988 , 319, 990-8	59.2	665
32	Significance and correlations of molecular analysis results in patients with Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. <i>American Journal of Medicine</i> , 1988 , 85, 639-44	2.4	38
31	Clinical studies of alpha-interferons in chronic myelogenous leukemia. <i>Cancer Treatment Reviews</i> , 1988 , 15 Suppl A, 49-53	14.4	2
30	Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapy. <i>Journal of Clinical Oncology</i> , 1988 , 6, 1569-75	2.2	40
29	Malignancy-associated Sweet's syndrome: review of the world literature. <i>Journal of Clinical Oncology</i> , 1988 , 6, 1887-97	2.2	309

28	A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. <i>Journal of Clinical Oncology</i> , 1988 , 6, 1328-34	2.2	191
27	Clinical Studies of Alpha and Gamma Interferons in Chronic Myelogenous Leukemia 1988 , 127-139		
26	Characteristics of accelerated disease in chronic myelogenous leukemia 1988 , 61, 1441		1
25	Molecular characteristics of chronic myelogenous leukemia in blast crisis. <i>Cancer Genetics and Cytogenetics</i> , 1987 , 27, 349-56		36
24	Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. <i>American Journal of Medicine</i> , 1987 , 83, 445-54	2.4	241
23	Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia. <i>Acta Haematologica</i> , 1987 , 78 Suppl 1, 70-4	2.7	5
22	Clinical and prognostic features of patients with Philadelphia chromosome-positive chronic myelogenous leukemia and extramedullary disease. <i>Cancer</i> , 1987 , 59, 297-300	6.4	47
21	Therapy of chronic myelogenous leukemia. <i>Cancer</i> , 1987 , 59, 664-7	6.4	22
20	The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. <i>Cancer</i> , 1987 , 59, 1739-43	6.4	68
19	Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high-dose decadron. <i>Cancer</i> , 1987 , 60, 1708-12	6.4	26
18	Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia--a pilot study. <i>American Journal of Hematology</i> , 1987 , 24, 341-50	7.1	35
17	Molecular analysis of chromosome 22 breakpoints in adult Philadelphia-positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 1987 , 67, 55-9	4.5	26
16	Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. <i>Cancer</i> , 1986 , 58, 2023-30	6.4	54
15	Chronic myelogenous leukaemia: haematological remissions with alpha interferon. <i>British Journal of Haematology</i> , 1986 , 64, 87-95	4.5	59
14	Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. <i>New England Journal of Medicine</i> , 1986 , 314, 1065-9	59.2	594
13	Rearrangement in the breakpoint cluster region and the clinical course in Philadelphia-negative chronic myelogenous leukemia. <i>Annals of Internal Medicine</i> , 1986 , 105, 673-9	8	53
12	Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. <i>Journal of Clinical Oncology</i> , 1986 , 4, 1101-9	2.2	69
11	Clinical toxicity of interferons in cancer patients: a review. <i>Journal of Clinical Oncology</i> , 1986 , 4, 234-43	2.2	534

10	Pharmacokinetics, Single-Dose Tolerance, and Biological Activity of Recombinant Gamma-Interferon in Cancer Patients. <i>Oncology</i> , 1985 , 42, 41-50	3.6	14
9	Down-regulation of peripheral blood cell interferon receptors in chronic myelogenous leukemia patients undergoing human interferon (HuIFN alpha) therapy. <i>International Journal of Cancer</i> , 1985 , 36, 23-8	7.5	40
8	The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. <i>Virology</i> , 1985 , 140, 230-8	3.6	149
7	Immune restoration and/or augmentation of local graft versus host reaction by traditional Chinese medicinal herbs. <i>Cancer</i> , 1983 , 52, 70-3	6.4	34
6	Rheumatoid factors in the sera of patient with gastrointestinal carcinoma. <i>Cancer</i> , 1983 , 52, 2156-61	6.4	18
5	Objective evaluation of local xenogeneic graft-versus-host reaction by computerized radioisotope imaging (CRI). <i>Journal of Immunological Methods</i> , 1983 , 61, 133-9	2.5	
4	The immune restorative effect of Isoprinosine administration on the local graft-versus-host reaction of cancer patients. <i>Clinical Immunology and Immunopathology</i> , 1983 , 28, 96-100		4
3	Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. <i>Annals of Internal Medicine</i> , 1983 , 99, 789-92	8	75
2	The immune restorative effect of cimetidine administration in vivo on the local graft-versus-host reaction of cancer patients. <i>Clinical Immunology and Immunopathology</i> , 1982 , 24, 155-60		33
1	Studies of natural killer cell activity and antibody-dependent cell-mediated cytotoxicity among patients with acute leukemia in complete remission. <i>Cancer Immunology, Immunotherapy</i> , 1982 , 14, 96-8	7.4	12